Two stages of development are required to achieve commercialisation. Stage one consists of phase 1/2 clinical trials for influenza along with a number of pre-clinical studies for influenza and TB. The clinical trial will demonstrate safety and initial immunisation effectiveness in humans. The pre-clinical work will help refine further the ideal doses to use and the vaccination schedules for both influenza and TB.

Stage two will consist of phase 2/3 clinical trials for influenza to gain marketing authorisation. In parallel to this, development will be continued for TB, and exploration of other uses for the technology will be made. Stage one requires $15 million; stage two requires $35 million.